Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This trial is designed to evaluate the efficacy and safety of 3 fixed dose levels of
bremelanotide, administered subcutaneously on an as-needed basis under conditions of home
use, for the treatment of female sexual arousal disorder (FSAD), hypoactive sexual desire
disorder (HSDD), or mixed FSAD/HSDD in premenopausal women.